Kaeley GS, et al. - Experts conducted a posthoc analysis of the MUSICA trial to compare imaging and clinical disease activity measures in obese and nonobese patients with rheumatoid arthritis (RA). They categorized the patients by baseline body mass index as normal (< 25), overweight (≥ 25 to < 30), or obese (≥ 30). Worse clinical and ultrasonographic responses were seen in obese patients with RA than nonobese patients, which were partly overcome with time. If adalimumab (ADA) is initiated with high-dose (20 mg/week) rather than low-dose MTX, obese patients may experience better and faster clinical improvements.